Sydney M Crago

Leos is supported by emerging data from a randomized controlled clinical trial, further validating its safety and efficacy.

A decision on a longer dosing duration for the high-dose formulation is expected by April 20, 2025.

This treatment is already approved for both diabetic macular edema (DME) and NIU-PS outside the US, including in 17 European countries.

What do ophthalmologists consider the key advancements in treating glaucoma over the last several decades?

We asked ophthalmologists what stands out to them in the history of treating glaucoma and where future treatments might be heading.

Ying Han, MD, PhD discusses glaucoma management strategies, including transitioning care between ophthalmologists and optometrists, improving diagnosis, and the hope for future glaucoma developments.

Shah discusses several studies from the IRIS registry and plans for a retina program at next year's event to address the growing interest in retina procedures and techniques.

Yvonne Ou, MD, a professor of ophthalmology at the University of California San Francisco, spoke about lifestyle modifications for glaucoma at this year's Glaucoma 360 meeting.

M. Roy Wilson, presented the Shaffer-Hetherington-Hoskins Lecture at the Glaucoma 360 meeting held in San Francisco, California. This lecture was entitled, "Rethinking Race as a Risk Factor for Glaucoma: What Really Matters?"

Ophthalmology Times spoke with Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis about how her research can align with human glaucoma research to move the entire field

Sunita Radhakrishnan, MD, shares insights on the use of electric neurostimulation and its potential use in the treatment of glaucoma, as evidenced by its current use in Europe and the upcoming trials for use in the US.

Shan Lin, MD, speaks to the new MIGS entering the glaucoma space and providing additional options for patients and providers as they work to preserve vision and work towards a better future for glaucoma treatment options.

Andrew Iwach, MD, co-founder of the Glaucoma 360 meeting shares that value this meeting has for residents and fellows as they embark on their careers and the future additions to the meeting that will include retina discussions.

Inder Paul Singh, MD, speaks to the potential of artificial intelligence (AI) in the management of the glaucoma disease state as well as the current challenges of drug delivery in treating patients with glaucoma.

John Berdahl, MD, discusses a non-surgical, non-drug treatment for glaucoma approved by the FDA in 2024. The pump uses negative pressure to lower eye pressure by an average of 39% in clinical trials, with a good safety profile.

Andrew Iwach, MD, shares how Glaucoma 360 got its start and how today's meeting focuses on innovation that can benefit patients with glaucoma as the condition is monitored and treated.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

Look back on some of the top stories on Modern Retina from 2024 as we gear up for an incredible 2025.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

The report details the results of preclinical discovery, engineering and characterization studies evaluating the safety, retinal cell transduction, transgene expression and clinical activity of proprietary evolved intravitreal vector R100 and 4D-150.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

The phase 2b/3 clinical trial (NCT05683496) evaluated izokibep versus placebo in non-infectious, non-anterior uveitis.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.

EXG102 and EXG202 are investigational gene therapy candidates for wet age-related macular degeneration that are in development.

In this series, experts in the field advise current residents and offer insight into how they can make the most of their time and experience moving forward with their careers.